8-K Announcements
6Material company update
Mar 13, 2026·SEC
Material company update
Jan 8, 2026·SEC
Material company update
Sep 4, 2025·SEC
Bone Biologics Corporation(BBLG)Earnings, Financials & Key Ratios
BBLG•NASDAQ
$1.35
Price updated Jun 27, 2026
AboutBone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.Show more
- Revenue$0
- EBITDA-$3M-1931150.3%
- Net Income-$3M+24.4%
- EPS (Diluted)-2.65+45.1%
- ROE-70.17%+45.5%
BBLG Price & Volume
Bone Biologics Corporation (BBLG) stock price & volume — 10-year historical chart
Loading chart...
Pre-Revenue Clinical Development Drives Persistent Capital Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's reliance on external funding to cover operating losses
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"Bone Biologics remains a high-risk, pre-revenue entity entirely dependent on the successful regulatory advancement of its NELL-1 protein technology. The company's financial profile is characterized by consistent quarterly operating losses, which reached $805.1K in 2026Q1, and a rapidly depleting cash runway that necessitates potential future dilutive financing. Investors should monitor the firm's ability to reach commercial milestones, as the current $88.9 million accumulated deficit underscores the significant capital destruction inherent in its long-term R&D-focused business model."
Verdict Logic
which totaled $766.0K in 2026Q1, combined with a shrinking cash balance of $4.5 million, suggests a high probability of further shareholder dilution.
BBLG Growth Metrics
Bone Biologics Corporation (BBLG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM32.97%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.13%
Return on Capital
10 Years-98.67%
5 Years-98.67%
3 Years-139.35%
Last Year-73.01%
Peers Comparison
Key metrics vs top competitors for Bone Biologics Corporation (BBLG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.35 | $2.42M | -0.51 | — | — | -70.17% | — | |
| $0.42 | $58.92M | 14.00 | 14.21% | 1.5% | 3.68% | — | |
| $9.30 | $1.41B | -9.69 | 24.95% | -21.07% | -443.09% | — | |
| $86.25 | $11.63B | 22.00 | 16.65% | 18.92% | 13.04% | — | |
| $9.78 | $395.32M | -4.29 | 2.85% | -7.27% | -13.44% | — | |
| $15.10 | $202.35M | -19.87 | -5.91% | -9.52% | -7.74% | — |
Compare BBLG vs Peers
Bone Biologics Corporation (BBLG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BBLG SEC Filings & Documents
Bone Biologics Corporation (BBLG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BBLG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BBLG Frequently Asked Questions
Bone Biologics Corporation (BBLG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BBLG profitable?
Bone Biologics Corporation (BBLG) reported a net loss of $2.9M for fiscal year 2025.
Dividend & Returns
What is BBLG's return on equity?
Bone Biologics Corporation (BBLG) has a return on equity (ROE) of -70.2%. Negative ROE indicates the company is unprofitable.
What is Bone Biologics Corporation's free cash flow?
Bone Biologics Corporation (BBLG) had negative free cash flow of $2.6M in fiscal year 2025, likely due to heavy capital investments.